Milan, 29 December 2017 – Hefei SARI V-Capital Management Co.,Ltd has acquired 90% of NMS Group, holding company of Nerviano Medical Sciences Group, from Fondazione Regionale per la Ricerca Biomedica (i.e. Regional Foundation for Biomedical Research), still holding a stake equal to 10%.
The completion of the acquisition process is expected within the first quarter of 2018.
Pedersoli Studio Legale has advised Hefei SARI V-Capital Management with a team led by Antonio Pedersoli (Equity Partner) and composed of Luca Saraceni (Partner) and Jean-Daniel Regna-Gladin (Senior Associate) in relation to corporate matters, while Maura Magioncalda (Equity Partner) and Alessandra De Cantellis (Partner) have provided legal assistance in relation to debt restructuring issues.
Fondazione Regionale per la Ricerca Biomedica has been advised by Lipani Catricalà & Partners and Macchi di Cellere Gangemi with their respective teams composed of Damiano Lipani and Claudio Visco (both Senior Partners) and Giorgio Lezzi and Ernesto Pucci (both Partners).
NMS Group has been advised by Studio CMS with a team led by Mauro Battistella (Partner), also in relation to the company’s debt restructuring. In this regard, UniCredit has been advised by the international law firm Gianni, Origoni, Grippo, Cappelli & Partners with a team composed by Roberto Cappelli and Matteo Bragantini (both Partners), Stefania Lo Curto (Counsel) and Leonarda Martino (Associate).
Leonardo&Co and Bank of China have acted as financial advisors, respectively, of NMS Group and Hefei SARI V-Capital Management.
FOR FURTHER INFORMATION:
Pedersoli Studio Legale
Tel: +39 02 30 30 51
Ad Hoc Communication Advisors
Tel. +39 335 1415584